The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis - a double-blind, multicentre, randomized placebo-controlled dose-response study
Abstract
In a double-blind multicentre randomised placebo-controlled dose-response study of the feverfew CO2-extract MIG-99 (n=147), a predefined subgroup with frequent migraine showed a dose-dependent reduction in attack frequency, with 6.25 mg three times daily giving the most favourable benefit-risk ratio and tolerability comparable to placebo.
Referenced for these plants
How to cite
Pfaffenrath, V., Diener, H.C., Fischer, M., Friede, M. and Henneicke-von Zepelin, H.H (2002) 'The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis - a double-blind, multicentre, randomized placebo-controlled dose-response study', Cephalalgia, 22(7), pp. 523-532. doi:10.1046/j.1468-2982.2002.00396.x
This reference is part of the evidence base for the Omnia Sana plant database. Source links open the original publication; Omnia Sana does not host third-party content.